CareSens Air
i-SENS
What it is
A 15-day CGM marketed in Australia for adults with diabetes, with optional calibration and a 30-minute warm-up. A September 2026 pooled study adds accuracy evidence for the current algorithm, retrospectively applied to recorded sensor signals; it does not establish a commercial AID pairing.
Editorial review: .
Most recent recorded citation date: 2026-09-15. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Accuracy: The pooled current-algorithm analysis reports 9.5% MARD across 17,655 laboratory comparator pairs from 163 adults. The retained score has not been recalibrated against this manufacturer-funded retrospective analysis.[5]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Score limitations. The existing numerical ratings remain editorial and have not been recalibrated against the newly reviewed accuracy study. Meeting proposed eCGM performance criteria is not regulatory approval, a head-to-head comparison or proof of clinical benefit.
Default calculation: 45 × 20 + 40 × 15 + 10 × 15 + 88 × 10 + 88 × 10 + 60 × 10 + 80 × 10 + 0 × 5 + 60 × 5 = 5110; divide by total weight 100. Unrounded weighted result: 51.1.
The pooled current-algorithm analysis reports 9.5% MARD across 17,655 laboratory comparator pairs from 163 adults. The retained score has not been recalibrated against this manufacturer-funded retrospective analysis.[5]
The five-minute transmission interval is a reporting cadence, not a measured individual physiological delay.[1]
The reviewed Australian instructions describe a phone app, phone-connected watch and sharing functions. They do not establish a commercial AID pairing.[4]
The Australian label permits up to 15 days; a maximum wear period is not guaranteed sensor survival.[4]
Calibration is optional under the reviewed Australian instructions; meter backup is still required for mismatched or unavailable readings.[4]
The Australian manual includes very-low, low, high and rapid-change alerts. Notification and mute settings affect their delivery; no alert-outcome benefit is inferred.[4]
The Australian specification is 35.2 × 19.2 × 5.0 mm and 4.5 ± 0.5 g for the transmitting part. Comfort is an editorial assessment.[4]
Pharmaco advertises Australian direct purchase and subscriptions for adults. Individual funding and nationwide pharmacy stock are not established here.[2]
Editor’s take
Scores are editorial judgments about the evidence and practical features, not measured comparative performance or a probability of success.
The full picture
CareSens Air is a glucose sensor marketed by Pharmaco in Australia for adults aged 18 and over with type 1 or type 2 diabetes. The reviewed Australian manual permits up to 15 days, with optional calibration and a 30-minute warm-up. Older studies used a different algorithm with mandatory calibration and a longer warm-up, so versions should not be interchanged.245
New accuracy evidence, with important limits
The study published 15 September 2026 pooled three adult investigations: 164 participants and 168 primary sensors overall, but 163 participants, 163 sensors and 17,655 laboratory comparator pairs for accuracy. MARD was 9.5%; 92.4% of pairs met the study's 20/20 agreement definition, using a 100 mg/dL (5.6 mmol/L) cutoff between absolute and relative error. These were mixed diabetes populations. The manufacturer retrospectively generated readings from raw signals using its current optional-calibration algorithm; the investigators performed the statistical analysis. The manufacturer funded the work.5
The analysis was neither a head-to-head comparison nor a randomized clinical-outcome trial. Its eCGM criteria are a proposed framework, not regulator clearance of AID compatibility. Children and pregnant participants were not included. Sensor survival used all 168 sensors: the Kaplan–Meier estimate at 15 days plus 30 minutes was 90.2% (95% CI 84.2–94.0%), with 15 failures and 39 censored sensors. Eight participants had mild, nonserious device effects. These findings are specific to the study design and reprocessed algorithm.5
Wear, water and alerts
The Australian specification lists the transmitting part as 35.2 × 19.2 × 5.0 mm, weighing 4.5 ± 0.5 g. The sensor's IP48 rating includes immersion to 1 metre for 24 hours under test conditions; that does not establish the phone's water resistance. Readings transmit every five minutes, which is not a measurement of physiological lag.41
The app includes very-low, low, high and rapid-change alerts. Phone notification permissions, volume and mute settings matter. The watch app receives data from the phone, not directly from the sensor; disconnected components can prevent readings and alerts. These practical features do not themselves prove improved clinical outcomes.4
Safety and the local instructions
The Australian manual does not permit use in people under 18, pregnancy or breastfeeding, dialysis, or critical illness. It requires sensor removal before specified procedures, including MRI, CT and X-rays. Use a blood glucose meter for treatment decisions when readings conflict with symptoms or expectations or when a current reading is unavailable. Vitamin C injections or infusions can falsely raise readings; the manual provides separate interference guidance. Optional calibration does not remove those backup requirements, and calibration during rapid glucose changes can reduce accuracy.46
Access and compatibility
Pharmaco advertises direct Australian purchase and subscriptions. ARTG 496627, dated 3 July 2025, identifies an I-Sens invasive interstitial-fluid glucose monitoring system sponsored by Pharmaco; the public entry does not name the retail model. This review does not establish NDSS funding, nationwide pharmacy stock or a commercial AID integration. The paper's conclusions do not substitute for a regulator's decision or a named compatible pump's label.235
The manufacturer separately announced a CareSens Air receiver rollout in European markets. That announcement is not proof of Australian receiver availability or a pediatric indication. CareSens Air 2 is a separate successor record; the accuracy analysis here concerns CareSens Air's current algorithm.75
Sources
- [1]CareSens Air current specifications · Manufacturer
- [2]
- [3]TGA ARTG496627, I-Sens CGM sponsored by Pharmaco · Regulatory decision · 2025-07-03 — The public ARTG page identifies the sponsor, manufacturer and device category; it does not name the retail model.
- [4]Australian CareSens Air instructions · Manufacturer — Official Australian distributor-linked manual PCGAA-000148 REV0 2025-08; indication p12, watch p97, optional calibration p106, alerts pp118–123, and specifications pp154–155.
- [5]Performance of the i-SENS CareSens Air CGM System in Compliance with the European CGM (eCGM) Clinical Performance Criteria: A Pooled Analysis · Peer-reviewed study · 2026-09-15 — Three studies pooled and raw signals retrospectively reprocessed by the manufacturer. Overall164 participants/168 primary sensors; accuracy163 participants/163 sensors/17,655 laboratory comparator pairs. Proposed eCGM criteria are not regulatory approval.
- [6]
- [7]i-SENS announces CareSens Air receiver rollout · Manufacturer — European rollout announcement; this does not verify Australian receiver availability or pediatric indication.